m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation

m6A Modification:
Crosstalk ID	M6ACROT05021				[1]
Non-coding RNA linc01305 IGF2BP2 lncRNA miRNA circRNA Direct Enhancement m⁶A modification Htr3a Htr3a IGF2BP2 : m⁶A sites
m6A Regulator	Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)			READER	Regulator Info
m6A Target	5-hydroxytryptamine receptor 3A (HTR3A)				Targert Gene
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type	Non-coding RNA (ncRNA)
Epigenetic Regulator	Long intergenic non-protein coding RNA 1305 (LINC01305)			LncRNA	View Details
Regulated Target	Insulin like growth factor 2 mRNA binding protein 2 (IGF2BP2)				View Details
Crosstalk Relationship	ncRNA → m6A			Enhancement
Crosstalk Mechanism	ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary	LINC01305 promotes metastasis and proliferation of esophageal squamous cell carcinoma through interacting with IGF2BP2 and IGF2BP3 to stabilize 5-hydroxytryptamine receptor 3A (HTR3A) mRNA
Responsed Disease	Esophageal Squamous Cell Carcinoma		ICD-11: 2B70.1		Disease Info
In-vitro Model	KYSE-180	Esophageal squamous cell carcinoma	Homo sapiens		CVCL_1349
	TE-5	Esophageal squamous cell carcinoma	Homo sapiens		CVCL_1764
	KYSE-150	Esophageal squamous cell carcinoma	Homo sapiens		CVCL_1348
	KYSE-510	Esophageal squamous cell carcinoma	Homo sapiens		CVCL_1354
	KYSE-140	Esophageal squamous cell carcinoma	Homo sapiens		CVCL_1347

Full List of Potential Compound(s) Related to This m6A-centered Crosstalk

5-hydroxytryptamine receptor 3A (HTR3A)		49 Compound(s) Regulating the Target	Click to Show/Hide the Full List
Compound Name	Dolasetron		Approved	[2]
Synonyms	Dolasetronum; Dolasteron; Anzemet (TN); Dolasetron (INN); Dolasetron [INN:BAN]; Dolasetronum [INN-Latin]; 3-oxooctahydro-2h-2,6-methanoquinolizin-8-yl 1h-indole-3-carboxylate Click to Show/Hide
MOA	Antagonist
External Link	CID: 3033818 TTD: D00YLW DrugBank: DB00757
Compound Name	Palonosetron		Approved	[3]
Synonyms	Aloxi; Onicit; Palonosetron [INN]; Aloxi (TN); RS 25233-197; RS 25259-197; RS-25233-197; RS-25259-197; (S-(R,R))-2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one Click to Show/Hide
MOA	Antagonist
Activity	Ki = 0.03162 nM
External Link	CID: 6337614 TTD: D04FVU DrugBank: DB00377
Compound Name	Alosetron		Approved	[4]
Synonyms	Lotronex; Lotrpnex; ALOSETRON HYDROCHLORIDE; Alosetron HCl; Alosetron hydrochloride [USAN]; Alosetron monohydrochloride; GR 68755; GR 68755X; GR 68755c; GR68755; Alosetron (INN); Alosetron [INN:BAN]; Alosetron hydrochloride (USAN); GR-68755C; Lotronex (TN); Lotrpnex (TN); 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido(4,3-b)indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-, monohydrochloride; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:1); 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol; 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-(9CI); 2,3,4,5-Tetrahydro-5-methyl-2-((5-methyl-1H-imidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one; 2,3,4,5-Tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyrido(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-((5-methylimidazol-4-yl)methyl)-1H-pyridol(4,3-b)indol-1-one monohydrochloride; 2,3,4,5-tetrahydro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one, monohydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one hydrochloride; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one; 5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-3,4-dihydropyrido[4,3-b]indol-1-one hydrochloride Click to Show/Hide
MOA	Antagonist
Activity	Ki = 0.5 nM
External Link	CID: 2099 TTD: D06GKN DrugBank: DB00969
Compound Name	Tropisetron		Approved	[5]
Synonyms	Navoban; Novaban; TKT; ICS-205930; Navoban (TN); Tropisetron (INN); [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] 1H-indole-3-carboxylate; (3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl 1H-indole-3-carboxylate Click to Show/Hide
MOA	Antagonist
Activity	Ki = 2.7 nM
External Link	CID: 656665 TTD: D0K0KH DrugBank: DB11699
Compound Name	Procaine		Approved	[6]
Synonyms	Allocaine; Anticort; Anuject; Duracaine; Gerokit; Gerovital; Jenacain; Jenacaine; Nissocaine; Norocaine; Novocain; Novocaine; Procain; Procaina; Procainum; Scurocaine; Spinocaine; Solution of novocain; Factor H3; SP01; SP01A; Stoff H3; Vitamin H3; Anticort (TM); Diethylaminoethyl p-aminobenzoate; Gerovital H-3; Novocain (TN); P-Aminobenzoyldiethylaminoethanol; P-Aminobenzyoyldiethylaminoethanol; Procaina [INN-Spanish]; Procaine (INN); Procaine [INN:BAN]; Procaine, base; Procainum [INN-Latin]; SP-01A; Solution of novocain (TN); Beta-Diethylaminoethyl 4-aminobenzoate; P-Aminobenzoic acid 2-diethylaminoethyl ester; Beta-(Diethylamino)ethyl 4-aminobenzoate; Beta-(Diethylamino)ethyl p-aminobenzoate; BENZOIC ACID,4-AMINO,2-DIETHYLAMINOETHYL ESTER PROCAIN BASE; Benzoic acid, 4-amino-, 2-(diethylamino)ethyl ester; Benzoic acid, p-amino-, 2-(diethylamino)ethyl ester; 2-(Diethylamino)ethyl 4-aminobenzoate; 2-(Diethylamino)ethyl p-aminobenzoate; 2-(Diethylamino)ethyl-4-aminobenzoate; 2-Diethylaminoethyl 4-aminobenzoate; 2-Diethylaminoethyl p-aminobenzoate; 2-Diethylaminoethylester kyseliny p-aminobenzoove; 2-Diethylaminoethylester kyseliny p-aminobenzoove [Czech]; 4-Aminobenzoesaeure-beta-diethylaminoethylester; 4-Aminobenzoic acid 2-(diethylamino) ethyl ester; 4-Aminobenzoic acid diethylaminoethyl ester Click to Show/Hide
MOA	Antagonist
External Link	CID: 4914 TTD: D0TZ1G DrugBank: DB00721
Compound Name	Levetiracetam		Approved	[5]
Synonyms	102767-28-2; Keppra; (S)-2-(2-Oxopyrrolidin-1-yl)butanamide; Keppra XR; Levetiracetamum; ucb L059; (2S)-2-(2-oxopyrrolidin-1-yl)butanamide; UCB-L 059; UCB-L059; Spritam; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; SIB-S1; UNII-44YRR34555; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-; UCB-22059; Levetiracetamum [INN-Latin]; Levetiractam; CHEBI:6437; ucb L060; Levetiracetam In Sodium Chloride; 44YRR34555; Levroxa; 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-,; Leviteracetam; Torleva; Levetiracetam [INN]; Etiracetam levo-isomer; Keppra (TN); L-059; Etiracetam, S-isomer; Keppra, Keppra XR),Levetiracetam; Levetriacetam Click to Show/Hide
MOA	Antagonist
External Link	CID: 5284583 TTD: D0E1XL DrugBank: DB01202
Compound Name	Palonosetron + fosnetupitant		Approved	[7]
MOA	Antagonist
External Link	TTD: D0K5IP
Compound Name	Cilansetron		Phase 3	[8]
Synonyms	Calmactin; DU-123265; KC-9946; Cilansetron (USAN/INN) Click to Show/Hide
MOA	Modulator
External Link	CID: 6918107 TTD: D0Z2MB DrugBank: DB04885
Compound Name	BEMESETRON		Discontinued in Phase 3	[9]
Synonyms	3-Tropanyl-3,5-dichlorobenzoate; MDL 72222; MDL-72222; C15H17Cl2NO2; CHEMBL376379; 40796-97-2; Tropyl 3,5-dichlorobenzoate; 8-Methyl-8-azabicyclo[3.2.1]oct-3-yl 3,5-dichlorobenzoate; Bemesetron [USAN:INN]; Bemesetronum [INN-Latin]; 3,5-Dichloro-benzoic acid 8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl ester; SR-01000075587; Tropanyl 3,5-dichlorobenzoate; 1alphaH,5alphaH-Tropan-3alpha-yl 3,5-dichlorobenzoate; endo-8-Methyl-8-azabicyclo(3.2.1)oct-3-yl 3,5-dichlorobenzoate; (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 3,5-dichlorobenzo Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 2.5 nM
External Link	CID: 671690 TTD: D0V3GT
Compound Name	YM-114		Discontinued in Phase 2	[10]
Synonyms	KAE-393; (R)-5-(2,3-Dihydro-1H-indol-1-ylcarbonyl)-4,5,6,7-tetrahydro-1H-benzimidazole hydrochloride Click to Show/Hide
MOA	Antagonist
External Link	CID: 132963 TTD: D02WGN
Compound Name	Norcisapride		Discontinued in Phase 2	[11]
Synonyms	84946-16-7; CHEMBL1748; 4-Amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidyl)benzamide; 4-amino-5-chloro-2-methoxy-N-(3-methoxy-4-piperidinyl)benzamide; (4-Amino-5-chloro-2-methoxy)-N-[3-methoxy(4-piperidyl)]benzamide; 4-amino-5-chloro-2-methoxy-N-(3-methoxypiperidin-4-yl)benzamide; Benzamide,4-amino-5-chloro-2-methoxy-N-[(3S,4R)-3-methoxy-4-piperidinyl]-, hydrochloride(1:1); EINECS 284-619-3; AC1MI81F; SCHEMBL593405; CTK4E8653; OMLDMGPCWMBPAN-UHFFFAOYSA-N; BDBM50301927; AKOS030254741; API0006151; DB-076176 Click to Show/Hide
MOA	Inhibitor
Activity	EC50 = 2300 nM
External Link	CID: 3019427 TTD: D0K1SZ
Compound Name	ATI-17000		Preclinical	[12]
Synonyms	CompB; J-113397; UNII-00M5444DIY; CHEMBL357076; 00M5444DIY; J113397; 1-[(3R,4R)-1-(cyclooctylmethyl)-3-(hydroxymethyl)piperidin-4-yl]-3-ethylbenzimidazol-2-one; 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; AC1NSK6N; J-113,397; 1-(1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl)-3-ethyl-1,3-dihydro-2H-benzimidazol-2-one; 256640-45-6; SCHEMBL875219; J 113397; GTPL1691; (+)-J-113397; ZINC1483900; BDBM50083230; NCGC00344513-02; 2H-Benzimidazol-2-one, Click to Show/Hide
MOA	Antagonist
External Link	CID: 5311194 TTD: D0M1YN
Compound Name	AS-8112		Terminated	[13]
MOA	Antagonist
External Link	TTD: D08KDP
Compound Name	BP4.879a		Terminated	[14]
MOA	Antagonist
External Link	CID: 5311254 TTD: D0V1SD
Compound Name	5-hydroxyindole		Investigative	[15]
Synonyms	1H-Indol-5-ol; 1953-54-4; INDOL-5-OL; 5-Hydroxy-1H-indole; Hydroxy-5 indole; 5-Indolol; UNII-320UN7XZYN; Hydroxy-5-indole; Hydroxy-5 indole [French]; CCRIS 4422; 5-Hydroxyindole, 97%; EINECS 217-782-6; MFCD00005677; NSC 87503; BRN 0112349; 320UN7XZYN; CHEBI:89649; LMIQERWZRIFWNZ-UHFFFAOYSA-N; NSC-87503; 5-hydroxy-indole; Hydroxy-5 indole [French]; 5-hydroxylindole; 5-hydroxy-indol; 5-hydroxy indole; 3fuh; 5H1; zlchem 359; 5Hydroxy-1H-indole; PubChem7263; 1-H-indol-5-ol; 1H-indol-5-ol.; 4b3c; ACMC-1BQT3; WLN: T56 BMJ GQ Click to Show/Hide
MOA	Modulator (allosteric modulator)
External Link	CID: 16054 TTD: D00EJS
Compound Name	TMB-8		Investigative	[16]
Synonyms	8-(Diethylamino)octyl 3,4,5-trimethoxybenzoate; TMB 8; 57818-92-5; TM-8; 8-(N,N-Diethylamino)octyl-3,4,5-trimethoxybenzoate; 3,4,5-Trimethoxybenzoic acid, 8-(diethylamino)octyl ester; C22H37NO5; AC1L1KGS; AC1Q67GP; Lopac-861804; Lopac0_000022; BSPBio_001503; GTPL4323; CHEMBL258764; SCHEMBL2173737; CTK5A7496; DTXSID70206532; CHEBI:107633; HMS1989L05; HMS1791L05; HMS3402L05; 53464-72-5 (hydrochloride); ZINC3875139; EI-110; AKOS030559942; MCULE-5343453436; CCG-204118; NCGC00162047-03; NCGC00162047-01; NCGC00014998-06 Click to Show/Hide
MOA	Blocker (channel blocker)
External Link	CID: 5494 TTD: D01WXA
Compound Name	1-(biphenyl-4-yl)-3-(4-(piperidin-1-yl)butyl)urea		Investigative	[17]
Synonyms	CHEMBL1086332; SCHEMBL13527422 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 7900 nM
External Link	CID: 46831055 TTD: D02OYL
Compound Name	10,11-dihydro-5H-dibenzo[b,f]azepine		Investigative	[18]
Synonyms	Iminodibenzyl; 494-19-9; 10,11-Dihydro-5H-dibenz[b,f]azepine; Iminobibenzyl; 2,2'-Iminodibenzyl; 2,2'-Iminobibenzyl; 5H-Dibenz[b,f]azepine, 10,11-dihydro-; RP 23669; UNII-262BX7OE3U; NSC 72110; 10,11-Dihydro-5-dibenz(b,f)azepine; 6,11-dihydro-5H-benzo[b][1]benzazepine; 10,11-Dihydrodibenz(b,f)azepine; EINECS 207-787-1; 10,11-Dihydro-5H-dibenz(b,f)azepine; BRN 0152732; CHEMBL63054; 5H-Dibenz(b,f)azepine, 10,11-dihydro-; AI3-39165; 262BX7OE3U; ZSMRRZONCYIFNB-UHFFFAOYSA-N Click to Show/Hide
MOA	Inhibitor
External Link	CID: 10308 TTD: D04KGK
Compound Name	4-Benzoxazo-2-yl-1,4-diazabicyclo[3.2.2]nonane		Investigative	[19]
Synonyms	CHEMBL611082; SCHEMBL373021; CXJLWJAYGMWLRR-UHFFFAOYSA-N; BDBM50309862 Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 13 nM
External Link	CID: 9794818 TTD: D07ZZD
Compound Name	3alpha-(2'-Indolecarbonyloxy)-nortropane		Investigative	[20]
Synonyms	CHEMBL596256; BDBM50304333 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 46226582 TTD: D0C3AJ
Compound Name	FLUPENTIXOLE		Investigative	[18]
Synonyms	(E)-Flupenthixol; beta-Flupenthixol; trans-flupenthixol; trans-(E)-Flupentixol; trans-Flupentixol; 53772-85-3; EINECS 258-759-0; UNII-895OJP78MJ; Flupentiol; 2709-56-0; 895OJP78MJ; Flupenthixol, Beta; FLUPENTHIXOL, Alpha; 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-, (E)-; (E)-4-(3-(2-(Trifluoromethyl)-9H-thioxanthen-9-ylidene)propyl)-1-piperazineethanol; 2-[4-[(3E)-3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol Click to Show/Hide
MOA	Inhibitor
External Link	CID: 5281878 TTD: D0M4RW
Compound Name	[3H]ramosetron		Investigative	[21]
MOA	Antagonist
External Link	CID: 91827343 TTD: D0O5PQ
Compound Name	3alpha-(1'-Methyl-2'-Indolecarbonyloxy)-tropane		Investigative	[20]
Synonyms	CHEMBL593963; BDBM50304334 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 46226590 TTD: D0S8ZJ
Compound Name	[3H]GR65630		Investigative	[22]
Synonyms	[3H]-GR65630 Click to Show/Hide
MOA	Antagonist
External Link	CID: 5311136 TTD: D0T3QZ
Compound Name	[3H](S)-zacopride		Investigative	[23]
Synonyms	GTPL4074 Click to Show/Hide
MOA	Antagonist
External Link	CID: 53321935 TTD: D0UV6L
Compound Name	BRL-24682		Investigative	[24]
Synonyms	Brl 24682; SCHEMBL7292676; CHEMBL301039; BDBM82519; PDSP2_001249; PDSP1_001265; 76272-78-1; CAS_76272-78-1; 4-amino-5-chloro-2-methoxy-N-(8-methyl-8-azabicyclo[3.2.1]octan-3-yl)benzamide; Benzamide, 4-amino-5-chloro-2-methoxy-N-(8-methyl-8-azabicyclo(3.2.1)oct-3-yl)-, endo- Click to Show/Hide
MOA	Inhibitor
External Link	CID: 9797313 TTD: D00PCE
Compound Name	6-(4-Methyl-piperazin-1-yl)-phenanthridine		Investigative	[25]
Synonyms	CHEMBL43193; 23441-13-6; 6-(4-methylpiperazin-1-yl)phenanthridine; CTK0I7937; DTXSID50433889; ZINC13778637; BDBM50063258; 6-(4-Methylpiperazino)phenanthridine; Phenanthridine, 6-(4-methyl-1-piperazinyl)- Click to Show/Hide
MOA	Inhibitor
External Link	CID: 9993659 TTD: D04AXY
Compound Name	trichloroethanol		Investigative	[26]
Synonyms	2,2,2-TRICHLOROETHANOL; 115-20-8; Trichlorethanol; Trichloroethyl alcohol; Ethanol, 2,2,2-trichloro-; 2,2,2-Trichloro-1-ethanol; (Hydroxymethyl)trichloromethane; 2,2,2-Trichloroethyl alcohol; 2,2,2-Trichloroethan-1-ol; C2H3Cl3O; UNII-AW835AJ62N; NSC 66407; beta-trichloroethanol; CCRIS 6763; CCl3CH2OH; EINECS 204-071-0; 2,2,2-trichloro-ethanol; 2,2,2-tris-chloroethanol; BRN 1697495; AW835AJ62N; CHEBI:28094; KPWDGTGXUYRARH-UHFFFAOYSA-N; .beta.,.beta.,.beta-Trichloroethanol; 2,2,2-Trichloroethanol, 99%; 4yas Click to Show/Hide
MOA	Modulator (allosteric modulator)
External Link	CID: 8259 TTD: D06IRE
Compound Name	(4-Quinolin-2-ylpiperazin-1-yl)acetic Acid		Investigative	[27]
Synonyms	CHEMBL468498; AC1LEONH; SCHEMBL13780710; A3329/0141355; BDBM50258497; AKOS009544966; 2-(4-quinolin-2-ylpiperazin-1-yl)acetic acid Click to Show/Hide
MOA	Inhibitor
External Link	CID: 715494 TTD: D0G3MD
Compound Name	1-phenylbiguanide		Investigative	[28]
Synonyms	phenylbiguanide; Phenyl biguanide; 102-02-3; Phenyldiguanide; Phenylguanide; phenyl diguanide; N-Phenyl-N'-guanylguanidine; N-phenylimidodicarbonimidic diamide; Biguanide, phenyl-; Imidodicarbonimidic diamide, N-phenyl-; UNII-W8PKA3T2I3; BIGUANIDE, 1-PHENYL-; C8H11N5; N-Phenyl-imidocarbonimidic diamide; EINECS 202-998-5; W8PKA3T2I3; CHEMBL13791; CHEBI:75377; P 1426; Imidodicarbonimidicdiamide, N-phenyl-; 1-(diaminomethylidene)-2-phenylguanidine; SR-01000075565; N-phenylbiguanide; N'-phenylbiguanide Click to Show/Hide
MOA	Agonist
External Link	CID: 4780 TTD: D0H4NK
Compound Name	(S)-zacopride		Investigative	[29]
Synonyms	CHEMBL28992; Tocris-1795; NCGC00025295-01; AC1O7H1O; SCHEMBL5373467; ZINC3961; GTPL2289; SCHEMBL16233195; PDSP2_001618; PDSP1_001634; BDBM50056419; UNII-9GN3OT4156 component FEROPKNOYKURCJ-CYBMUJFWSA-N; 4-Amino-N-(S)-1-aza-bicyclo[2.2.2]oct-3-yl-5-chloro-2-methoxy-benzamide; 4-amino-N-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-5-chloro-2-methoxybenzamide; 4-amino-N-[(8S)-1-azabicyclo[2.2.2]octan-8-yl]-5-chloro-2-methoxybenzamide Click to Show/Hide
MOA	Antagonist
Activity	Ki = 0.182 nM
External Link	CID: 6604914 TTD: D0I4BZ
Compound Name	PH-709829		Investigative	[30]
Synonyms	PTGWFYYEAUFEAS-ZYHUDNBSSA-N; CHEMBL403858; PHA-709829; SCHEMBL844377; GTPL3997; BDBM50377050 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 10107234 TTD: D0IP9V
Compound Name	2-(4-Benzyl-piperazin-1-yl)-benzothiazole		Investigative	[31]
Synonyms	2-(4-benzylpiperazin-1-yl)-1,3-benzothiazole; CHEMBL282234; 2-(4-benzylpiperazino)-1,3-benzothiazole; 35463-75-3; AC1LSALZ; Oprea1_030694; MLS001166194; SCHEMBL7760900; KS-00003DHQ; MolPort-002-878-239; HMS2852D05; ZINC20405012; BDBM50041381; AKOS005101332; MCULE-9582396226; 7P-339S; 1-(2-Benzothiazolyl)-4-benzylpiperazine; SMR000550026; 2-(4-benzylpiperazin-1-yl)benzo[d]thiazole; Z86230191 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 1484933 TTD: D0L1NS
Compound Name	[3H]granisetron		Investigative	[32]
Synonyms	[3H]-granisetron; [3H]-BRL-43694 Click to Show/Hide
MOA	Antagonist
Activity	Ki = 1.45 nM
External Link	CID: 3510 TTD: D0P2HR
Compound Name	meta-chlorphenylbiguanide		Investigative	[33]
Synonyms	m-Chlorophenylbiguanide; mCPBG; 1-(3-Chlorophenyl)biguanide; 1-(m-Chlorophenyl)biguanide; N-(3-Chlorophenyl)imidodicarbonimidic diamide; 48144-44-1; Imidodicarbonimidic diamide, N-(3-chlorophenyl)-; UNII-910A4X901V; M-Chlorophenylbiguanidine; 3-Chloro-Phenyl biguanide; 2-(3-chlorophenyl)-1-(diaminomethylidene)guanidine; CHEMBL13790; CHEBI:32347; N-(3-chlorophenyl)-N'-(diaminomethylene)guanidine; 910A4X901V; C8H10ClN5; Imidodicarbonimidicdiamide, N-(3-chlorophenyl)-; 1-carbamimidamido-N-(3-chlorophenyl)methanimidamide; 3-chlorophenyl-biguanide; [3H]meta-chlorophenylbiguanide Click to Show/Hide
MOA	Agonist
Activity	EC50 = 3800 nM
External Link	CID: 1354 TTD: D0SA4A
Compound Name	2-(1H-Imidazol-4-ylmethyl)-4-phenyl-thiazole		Investigative	[34]
Synonyms	CHEMBL289060; BDBM50014174 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 14742545 TTD: D0TJ6Z
Compound Name	CP-810123		Investigative	[19]
Synonyms	UNII-E6G4550EC4; CHEMBL604798; E6G4550EC4; BSNKYWSMUAGMDO-UHFFFAOYSA-N; 439608-12-5; SCHEMBL1459339; BDBM50309861; 1,4-Diazabicyclo(3.2.2)nonane, 4-(5-methyloxazolo(4,5-b)pyridin-2-yl)-; 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane; 4-(5-Methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]-nonane; 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diaza-bicyclo[3.2.2]nonane Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 5 nM
External Link	CID: 11184481 TTD: D0X7HD
Compound Name	bilobalide		Investigative	[35]
Synonyms	33570-04-6; Bilobalid; (-)-Bilobalide; UNII-M81D2O8H7U; CHEBI:3103; M81D2O8H7U; Bilobalide A; 4H,5aH,9H-Furo(2,3-b)furo(3',2':2,3)cyclopenta(1,2-c)furan-2,4,7(3H,8H)-trione, 9-(1,1-dimethylethyl)-10,10a-dihydro-8,9-dihydroxy-, (5aR-(3aS,5aalpha,8beta,8aS,9alpha,10aalpha))-; (3aS,8R,8aS,9R,10aS)-9-tert-butyl-8,9-dihydroxydihydro-9H-furo[2,3-b]furo[3',2':2,3]cyclopenta[1,2-c]furan-2,4,7(3H,8H)-trione; tert-butyl(dihydroxy)[ ]trione; C15H18O8; Bilobalide;; Bilobalide A;; ( )-Bilobalide; AC1L2K4G; MLS000563448 Click to Show/Hide
MOA	Blocker (channel blocker)
External Link	CID: 73581 TTD: D0B0TK
Compound Name	2-(4-Methyl-piperazin-1-yl)-quinoline		Investigative	[25]
Synonyms	N-methylquipazine; 2-(4-methylpiperazin-1-yl)quinoline; UNII-0YV1ZIR6S0; 0YV1ZIR6S0; CHEMBL288591; CHEBI:64164; quinoline, 2-(4-methyl-1-piperazinyl)-; Tocris-0566; Lopac-Q-107; Biomol-NT_000084; AC1L1JF3; Oprea1_654246; Lopac0_001000; SCHEMBL606721; BPBio1_001081; DTXSID8043731; CTK6I3065; HOMWNUXPSJQSSU-UHFFFAOYSA-N; MolPort-006-384-975; ZINC403653; 2-(4-Methylpiperazinyl)-quinoline; 1-(2-Quinolyl)-4-methylpiperazine; STK362919; BDBM50053631; AKOS005453926; MCULE-4786527390; CCG-205080 Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 0.4571 nM
External Link	CID: 5013 TTD: D0G2BS
Compound Name	4-((naphthalen-2-yloxy)methyl)piperidine		Investigative	[36]
Synonyms	4-[(2-Naphthyloxy)methyl]piperidine; CHEMBL453996; 946680-75-7; 4-[(naphthalen-2-yloxy)methyl]piperidine; CTK7D1529; ZINC14631494; BDBM50278526; AKOS000172158 Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 311 nM
External Link	CID: 24691160 TTD: D01FFX
Compound Name	MESULERGINE		Investigative	[37]
Synonyms	Mesulerginum; Mesulergina; Mesulergine [INN]; Mesulerginum [INN-Latin]; UNII-SML95FK06I; Mesulergina [INN-Spanish]; 64795-35-3; N'-(1,6-Dimethylergolin-8alpha-yl)-N,N-dimethylsulfamide; SML95FK06I; CQ 32085; CHEMBL12314; C18H26N4O2S; CHEBI:73378; 3-(1,6-Dimethyl-8alpha-ergolinyl)-1,1-dimethylsulfamid; NCGC00163168-01; DSSTox_RID_81540; DSSTox_CID_26324; DSSTox_GSID_46324; CU-32085; N'-[(8alpha)-1,6-dimethylergolin-8-yl]-N,N-dimethylsulfuric diamide; CAS-64795-35-3; AC1L2AKM; Biomol-NT_000077; AC1Q6V4R; GTPL206 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 68848 TTD: D0K5NZ
Compound Name	7-(piperidin-4-ylmethoxy)-2-naphthonitrile		Investigative	[36]
Synonyms	CHEMBL444985 Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 404 nM
External Link	CID: 44592241 TTD: D06QIQ
Compound Name	QUIPAZINE		Investigative	[38]
Synonyms	4774-24-7; 2-(piperazin-1-yl)quinoline; 2-Piperazin-1-yl-quinoline; 2-Piperazin-1-ylquinoline; Quinoline, 2-(1-piperazinyl)-; 2-(1-Piperazinyl)quinoline; Quipazine [INN]; 1-(2-Quinolinyl)piperazine; Quipazinum [INN-Latin]; Quipazina [INN-Spanish]; UNII-4WCY05C0SJ; 1-(2-Quinolyl)piperazine; 2-(1-Piperazinyl)chinolin; BRN 0196945; 4WCY05C0SJ; CHEMBL18772; 2-quinolylpiperazine; F3306-0004; Quipazinum; Quipazina; TPC-A004; MA-1291; Spectrum_001733; Tocris-0629; piperazin-1-yl-quinoline; AC1L1JEX; AC1Q4WAV; Spectrum4_001259 Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 3.7 nM
External Link	CID: 5011 TTD: D08BCF
Compound Name	5-chloro-3,4-dihydroquinazolin-2-amine		Investigative	[39]
Synonyms	CHEMBL401541; 2-Amino-5-chlor-3,4-dihydrochinazolin; 109319-86-0 Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 1051 nM
External Link	CID: 13702393 TTD: D0Y9TL
Compound Name	2-methyl-5-HT		Investigative	[40]
Synonyms	2-methyl-5-hydroxytryptamine; 2-Me-5-HT; 2-methylserotonin Click to Show/Hide
MOA	Agonist
Activity	Ki = 1200 nM
External Link	CID: 1574 TTD: D00CRA
Compound Name	5,6-dichloro-3,4-dihydroquinazolin-2-amine		Investigative	[39]
Synonyms	Anagrelide impurity 5; 2-Amino-5,6-dichloro-3,4-dihydroquinazoline; 444904-63-6; CHEMBL1548; 2-Quinazolinamine, 5,6-dichloro-1,4-dihydro-; W-202785; SCHEMBL1569300; CTK1D2410; DTXSID80432648; VBKOTIVQMCTTAQ-UHFFFAOYSA-N; ZINC29130869; BDBM50371434; AKOS030254941; 5,6-Dichloro-1,4-dihydro-2-quinazolinamine; 2-amino-5,6-dichloro-3,4dihydroquinazoline; FT-0722369 Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 172 nM
External Link	CID: 9904281 TTD: D08VGJ
Compound Name	SEROTONIN		Investigative	[25]
Synonyms	5-HYDROXYTRYPTAMINE; 3-(2-Aminoethyl)-1H-indol-5-ol; 50-67-9; Enteramine; 5-HT; Serotonine; Thrombotonin; Thrombocytin; Antemovis; Ds substance; Hippophain; Antemoqua; Substance DS; Substanz DS; 1H-Indol-5-ol, 3-(2-aminoethyl)-; 5-Hta; Tryptamine, 5-hydroxy-; 3-(2-Aminoethyl)indol-5-ol; Enteramin; UNII-333DO1RDJY; Indol-5-ol, 3-(2-aminoethyl)-; 5-Hydroxy-3-(beta-aminoethyl)indole; 3-(beta-Aminoethyl)-5-hydroxyindole; EINECS 200-058-9; 3-(2-Amino-ethyl)-1H-indol-5-ol; BRN 0143524; 333DO1RDJY; CHEBI:28790 Click to Show/Hide
MOA	Inhibitor
Activity	EC50 = 141 nM
External Link	CID: 5202 TTD: D0F6CD DrugBank: DB08839
Compound Name	A-987306		Investigative	[41]
Synonyms	SCHEMBL604437; CHEMBL519240; BDBM26226; MolPort-023-276-880; DJKJVWJQAVGLHJ-YPMHNXCESA-N; ZINC42887577; AKOS024457726; NCGC00370852-01; UNII-6BVK16R925 component DJKJVWJQAVGLHJ-YPMHNXCESA-N; (12S,17S)-6-(piperazin-1-yl)-11-oxa-3,5-diazatetracyclo[8.7.0.0^{2,7}.0^{12,17}]heptadeca-1(10),2(7),3,5-tetraen-4-amine; (-)-(7aS,11aS)-4-piperazin-1-yl-5,6,7a,8,9,10,11,11a-octahydro[1]benzofuro[2,3h]quinazolin-2-amine; (+/-)-(7aR,11aR)-5,6,7a,8,9,10,11,11a-Octahydro-4-(1-piperazinyl)-benzofuran[2,3-h]quinazolin-2-amine Click to Show/Hide
MOA	Inhibitor
External Link	CID: 44538833 TTD: D0F9QT
Compound Name	4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one		Investigative	[42]
Synonyms	AC-42; CHEMBL1242950; AC42; GTPL289; SCHEMBL4504348; ANTKBACNWQHQJE-UHFFFAOYSA-N; ZINC2022527; BDBM50326219; AKOS030284249; NCGC00485453-01; gamma-(4-Butylpiperidino)-2'-methylbutyrophenone; L019209; 4-(4-butylpiperdin-1-yl)-1-(2-methylphenyl)butan-1-one; 4-(4-butylpiperidin-1-yl)-1-(2-methylphenyl)butan-1-one Click to Show/Hide
MOA	Inhibitor
Activity	Ki >= 1000 nM
External Link	CID: 9948320 TTD: D0T2RY
2B70: Esophageal cancer		15 Compound(s) Regulating the Disease	Click to Show/Hide the Full List
Compound Name	Pembrolizumab		Approved	[43]
External Link	TTD: D08ANZ
Compound Name	Nivolumab		Approved	[43]
External Link	TTD: D00GOV
Compound Name	Claudiximab		Phase 3	[44]
Synonyms	IMAB-362; Anti-GC182 mAbs (cancer), Ganymed; Anti-GC182 monoclonal antibodies (cancer), Ganymed; Anti-CLDN18-2 mAbs (cancer), Ganymed; Anti-CLDN18-2 monoclonal antibodies (cancer), Ganymed Click to Show/Hide
External Link	TTD: D0B3ZC
Compound Name	Golnerminogene pradenovac		Phase 3	[45]
Synonyms	TNFerade (TN) Click to Show/Hide
External Link	TTD: D03QBT
Compound Name	DKN-01		Phase 2	[46]
External Link	TTD: DMF73Z
Compound Name	Pegamotecan		Phase 2	[47]
Synonyms	Prothecan; EZ-246; PEG-camptothecin; PEG-camptothecin, Enzon; Polyethylene glycol-camptothecin, Enzon Click to Show/Hide
External Link	CID: 11297617 TTD: D0D4CX
Compound Name	APR-246		Phase 2	[43]
Synonyms	Eprenetapopt Click to Show/Hide
External Link	CID: 52918385 TTD: D03XTY DrugBank: DB11684
Compound Name	Opdivo + Yervoy		Phase 3	[43]
External Link	TTD: D02VYE
Compound Name	Anti-NY-ESO-1 CAR-T cells		Phase 1/2	[48]
External Link	TTD: D0LJ2S
Compound Name	Anti-MUC1 CAR-T cells		Phase 1/2	[49]
External Link	TTD: D09KWN
Compound Name	CAR-T Cells targeting EpCAM		Phase 1/2	[50]
External Link	TTD: D08QYW
Compound Name	PCA062		Phase 1	[43]
External Link	TTD: D09WSR
Compound Name	Cellspan esophageal implant		Clinical trial	[43]
External Link	TTD: D0SW1D
Compound Name	PKI166		Discontinued in Phase 2	[51]
Synonyms	PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, > 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol Click to Show/Hide
External Link	CID: 6918403 TTD: D07GFF
Compound Name	Ramorelix		Discontinued in Phase 1	[52]
Synonyms	Hoe-013 Click to Show/Hide
External Link	CID: 25077455 TTD: D0S6AQ

References

Ref 1	linc01305 promotes metastasis and proliferation of esophageal squamous cell carcinoma through interacting with IGF2BP2 and IGF2BP3 to stabilize HTR3A mRNA. Int J Biochem Cell Biol. 2021 Jul;136:106015. doi: 10.1016/j.biocel.2021.106015. Epub 2021 May 19.
Ref 2	Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, do... Lancet Oncol. 2009 Feb;10(2):115-24.
Ref 3	Management of postoperative nausea and vomiting: focus on palonosetron. Ther Clin Risk Manag. 2009 Feb;5(1):21-34.
Ref 4	Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis. Am J Gastroenterol. 2009 Jul;104(7):1831-43; quiz 1844.
Ref 5	Emerging therapies for fibromyalgia. Expert Opin Emerg Drugs. 2008 Mar;13(1):53-62.
Ref 6	Local anesthetics have different mechanisms and sites of action at recombinant 5-HT3 receptors. Reg Anesth Pain Med. 2007 Nov-Dec;32(6):462-70.
Ref 7	2018 FDA drug approvals. Nat Rev Drug Discov. 2019 Feb;18(2):85-89. doi: 10.1038/d41573-019-00014-x.
Ref 8	Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.Expert Opin Investig Drugs.2005 Feb;14(2):185-93.
Ref 9	Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships. J Med Chem. 1992 Jan 24;35(2):310-9.
Ref 10	Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol. 1995 Nov;69(3):205-14.
Ref 11	mu-Opioid/5-HT4 dual pharmacologically active agents-efforts towards an effective opioid analgesic with less GI and respiratory side effects (Part I). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5679-83.
Ref 12	Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006 May;11(2):293-313.
Ref 13	Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar;11(1):137-51.
Ref 14	Pharmacological and regional characterization of [3H]LY278584 binding sites in human brain. J Neurochem. 1993 Feb;60(2):730-7.
Ref 15	The 5-HT3B subunit confers spontaneous channel opening and altered ligand properties of the 5-HT3 receptor. J Biol Chem. 2008 Mar 14;283(11):6826-31.
Ref 16	Characterization of interaction of 3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester with Torpedo californica nicotinic acetylcholine receptor and 5-hydroxytryptamine3 receptor. J Pharmacol Exp Ther. 1999 Jul;290(1):129-35.
Ref 17	Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and... J Med Chem. 2010 Jun 10;53(11):4379-89.
Ref 18	Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors. Eur J Med Chem. 2009 Jun;44(6):2667-72.
Ref 19	Discovery of 4-(5-methyloxazolo[4,5-b]pyridin-2-yl)-1,4-diazabicyclo[3.2.2]nonane (CP-810,123), a novel alpha 7 nicotinic acetylcholine receptor ag... J Med Chem. 2010 Feb 11;53(3):1222-37.
Ref 20	Synthesis of heteroaromatic tropeines and heterogeneous binding to glycine receptors. Bioorg Med Chem. 2009 Oct 1;17(19):6872-8.
Ref 21	Molecular cloning of human 5-hydroxytryptamine3 receptor: heterogeneity in distribution and function among species. Mol Pharmacol. 1995 Sep;48(3):407-16.
Ref 22	Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome. J Pharmacol Sci. 2007 Jul;104(3):263-73.
Ref 23	Autoradiographic distribution of [3H]-(S)-zacopride-labelled 5-HT3 receptors in human brain. J Neurol Sci. 1996 Dec;144(1-2):119-27.
Ref 24	Synthesis and structure-affinity relationships of novel N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)pyridine-3-carboxamides with potent serotoni... J Med Chem. 2003 Feb 27;46(5):702-15.
Ref 25	Novel potent and selective central 5-HT3 receptor ligands provided with different intrinsic efficacy. 2. Molecular basis of the intrinsic efficacy ... J Med Chem. 1999 May 6;42(9):1556-75.
Ref 26	Arginine 246 of the pretransmembrane domain 1 region alters 2,2,2-trichloroethanol action in the 5-hydroxytryptamine3A receptor. J Pharmacol Exp Ther. 2008 Mar;324(3):1011-8.
Ref 27	Specific targeting of peripheral serotonin 5-HT(3) receptors. Synthesis, biological investigation, and structure-activity relationships. J Med Chem. 2009 Jun 11;52(11):3548-62.
Ref 28	Allosteric interactions among agonists and antagonists at 5-hydroxytryptamine3 receptors. J Neurochem. 1995 Jul;65(1):104-10.
Ref 29	Pharmacological comparison of human homomeric 5-HT3A receptors versus heteromeric 5-HT3A/3B receptors. Neuropharmacology. 2001 Aug;41(2):282-4.
Ref 30	Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor:... Bioorg Med Chem Lett. 2008 Jun 15;18(12):3611-5.
Ref 31	Synthesis of 2-piperazinylbenzothiazole and 2-piperazinylbenzoxazole derivatives with 5-HT3 antagonist and 5-HT4 agonist properties. J Med Chem. 1994 Apr 29;37(9):1320-5.
Ref 32	Characterization of a human 5-hydroxytryptamine3 receptor type A (h5-HT3R-AS) subunit stably expressed in HEK 293 cells. Br J Pharmacol. 1996 Jul;118(5):1237-45.
Ref 33	Different efficacy of specific agonists at 5-HT3 receptor splice variants: the role of the extra six amino acid segment. Br J Pharmacol. 1998 Feb;123(4):661-6.
Ref 34	Aromatic thiazole derivatives: structurally novel and selective serotonin-3 receptor antagonists. J Med Chem. 1990 Jan;33(1):13-6.
Ref 35	Binding sites for bilobalide, diltiazem, ginkgolide, and picrotoxinin at the 5-HT3 receptor. Mol Pharmacol. 2011 Jul;80(1):183-90.
Ref 36	Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32.
Ref 37	Novel and highly potent 5-HT3 receptor agonists based on a pyrroloquinoxaline structure. J Med Chem. 1997 Oct 24;40(22):3670-8.
Ref 38	Novel, potent, and selective quinoxaline-based 5-HT(3) receptor ligands. 1. Further structure-activity relationships and pharmacological characteri... J Med Chem. 2009 Nov 12;52(21):6946-50.
Ref 39	Cyclic guanidines as dual 5-HT5A/5-HT7 receptor ligands: structure-activity relationship elucidation. Bioorg Med Chem Lett. 2008 Jan 1;18(1):256-61.
Ref 40	Pharmacological profile of YM-31636, a novel 5-HT3 receptor agonist, in vitro. Eur J Pharmacol. 2000 Dec 8;409(2):195-201.
Ref 41	cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia. J Med Chem. 2008 Nov 27;51(22):7094-8. doi: 10.1021/jm8007618.
Ref 42	Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. J Med Chem. 2010 Sep 9;53(17):6386-97. doi: 10.1021/jm100697g.
Ref 43	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 44	ClinicalTrials.gov (NCT01197885) Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer. U.S. National Institutes of Health.
Ref 45	ClinicalTrials.gov (NCT00051467) A Study of TNFerade Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer. U.S. National Institutes of Health.
Ref 46	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 47	ClinicalTrials.gov (NCT00080002) Efficacy of Pegamotecan (PEG-Camptothecin) in Localized or Metastatic Cancer of the Stomach or Gastroesophageal Junction. U.S. National Institutes of Health.
Ref 48	ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
Ref 49	ClinicalTrials.gov (NCT03706326) CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer
Ref 50	ClinicalTrials.gov (NCT03013712) A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer
Ref 51	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7642).
Ref 52	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008630)

m6A-centered Crosstalk Information

Cite M6AREG

Correspondence

Prof. Feng ZHU

Prof. Shuiping Liu

Visitor Map